Can heart failure patients ditch their pills? new study aims to find out

NCT ID NCT07631156

Not yet recruiting Disease control Sponsor: Kyungsub Song Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether heart failure patients whose heart function has returned to normal can safely stop taking two medications (sacubitril/valsartan and dapagliflozin or empagliflozin). Eighty adults whose heart failure was caused by a treatable condition like a heart valve problem will be randomly assigned to either stop these drugs step-by-step or continue taking them. The main goal is to see if their heart function stays stable over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stepwise withdrawal of sacubitril/valsartan (ARNI) and dapagliflozin or empagliflozin (SGLT2i)
What this could lead to: If successful, this could show that some heart failure patients who have recovered may be able to safely reduce their medication burden without their heart function worsening.
What could go wrong: This is a small, early pilot study with only 80 participants, so results may not apply to everyone. There is a risk that stopping these medications could cause heart function to decline or lead to hospitalization.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure heart valve disorder left ventricular failure systolic heart failure Ventricular Dysfunction, Left

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE HEART FAILURE WITH REDUCED EJECTION FRACTION VENTRICULAR DYSFUNCTION, LEFT

Contacts and locations

Locations

Ajou University Hospital

Suwon, Gyeonggi-do, 16499, South Korea
Keimyung University Dongsan Hospital

Daegu, Daegu, 42601, South Korea
Korea University Anam Hospital

Seoul, Seoul, 02841, South Korea
Pusan National University Yangsan Hospital

Yangsan, Gyeongsangnam-do, 50612, South Korea
Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 13620, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.